Compare Carvana Co (CVNA) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Ginkgo Bioworks Holdings Inc — how do they compare? Carvana Co trades at $63.8 (market cap $69.55B), while Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M). The key difference: Carvana Co is far larger — about 91.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| CVNA | DNA | |
|---|---|---|
Market Cap | $69.55B | $763.64M |
Volume | 7,671,750 | 3,204,177 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $15.83 |
52-Week Low | $56.27 | $5.48 |
Typical Hold Time | 28 Days | 7 Days |
Enterprise Value | $72.04B | $865.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.73, up 1.55% today, showing strong fundamental momentum with revenue surging to $20.32B in 2025 and net income reaching $1.41B. The stock has consistently beaten earnings expectations in recent quarters, though technical indicators signal bearish pressure with key resistance at $64-65. Recent news highlights Carvana as the 'best story' in autos with September sales beating estimates by 40%.
Carvana presents a compelling growth story with expanding profitability and aggressive capacity expansion, though high debt levels and volatile technical signals warrant caution. Analyst consensus targets $84.07 (32% upside) with 46% buy ratings, but investors face execution risks from inventory constraints and competitive pressures in the used car market.
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
